Inflammation conditions mature dendritic cells to retain the capacity to present new antigens but with altered cytokine secretion function

Journal of Immunology

Volumn 193, Issue 8, 2014, Pages 3851-3859

  Vega Ramos, Javier ^a,b   Roquilly, Antoine ^a,c   Zhan, Yifan ^b   Young, Louise J ^b   Mintern, Justine D ^b,d   Villadangos, Jose A ^a,b,d  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c HÔTEL DIEU   (France)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; BIOLOGICAL FACTOR; CYTOKINE; EOTAXIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 9; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCYTE CHEMOTACTIC PROTEIN 1; PATHOGEN ASSOCIATED MOLECULAR PATTERN; PROTEIN KC; RANTES; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; AUTACOID; CD8 ANTIGEN; HLA ANTIGEN CLASS 2; MARCH1 PROTEIN, MOUSE; OVALBUMIN; TLR9 PROTEIN, MOUSE; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA; UBIQUITIN PROTEIN LIGASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ARTICLE; CELL ACTIVATION; CELL MATURATION; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; DRUG DESIGN; IMMUNE RESPONSE; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MOLECULAR INTERACTION; MOUSE; NONHUMAN; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CBA MOUSE; CELL DIFFERENTIATION; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; LYMPHOCYTE ACTIVATION; T LYMPHOCYTE;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, CD8; CELL DIFFERENTIATION; CYTOKINES; DENDRITIC CELLS; HISTOCOMPATIBILITY ANTIGENS CLASS II; INFLAMMATION; INFLAMMATION MEDIATORS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; MICE, INBRED CBA; MICE, KNOCKOUT; OVALBUMIN; T-LYMPHOCYTES; TOLL-LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR-ALPHA; UBIQUITIN-PROTEIN LIGASES;

EID: 84907481831     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1303215     Document Type: Article

References (37)

1. Villadangos, J. A., P. Schnorrer, and N. S.Wilson. 2005. Control of MHC class II antigen presentation in dendritic cells: a balance between creative and destructive forces. Immunol. Rev. 207: 191-205.
2. Moffat, J. M., J. D. Mintern, and J. A. Villadangos. 2013. Control of MHC II antigen presentation by ubiquitination. Curr. Opin. Immunol. 25: 109-114.
3. Walseng, E., K. Furuta, B. Bosch, K. A. Weih, Y. Matsuki, O. Bakke, S. Ishido, and P. A. Roche. 2010. Ubiquitination regulates MHC class II-peptide complex retention and degradation in dendritic cells. Proc. Natl. Acad. Sci. USA 107: 20465-20470.
4. Reis e Sousa, C. 2004. Toll-like receptors and dendritic cells: for whom the bug tolls. Semin. Immunol. 16: 27-34.
5. Watts, C., M. A. West, and R. Zaru. 2010. TLR signalling regulated antigen presentation in dendritic cells. Curr. Opin. Immunol. 22: 124-130.
6. Wilson, N. S., G. M. Behrens, R. J. Lundie, C. M. Smith, J. Waithman, L. Young, S. P. Forehan, A. Mount, R. J. Steptoe, K. D. Shortman, et al. 2006. Systemic activation of dendritic cells by Toll-like receptor ligands or malaria infection impairs cross-presentation and antiviral immunity. Nat. Immunol. 7: 165-172.
7. Young, L. J., N. S. Wilson, P. Schnorrer, A. Mount, R. J. Lundie, N. L. La Gruta, B. S. Crabb, G. T. Belz, W. R. Heath, and J. A. Villadangos. 2007. Dendritic cell preactivation impairs MHC class II presentation of vaccines and endogenous viral antigens. Proc. Natl. Acad. Sci. USA 104: 17753-17758.
8. Platt,C.D. C., J. K. Ma,C. Chalouni, M. Ebersold, H. Bou-Reslan, R. A. D. Carano, I. Mellman, and L. Delamarre. 2010. Mature dendritic cells use endocytic receptors to capture and present antigens. Proc. Natl. Acad. Sci. USA 107: 4287-4292.
9. Henri, S., C. Siret, P. Machy, A. Kissenpfennig, B. Malissen, and L. Leserman. 2007. Mature DC from skin and skin-draining LN retain the ability to acquire and efficiently present targeted antigen. Eur. J. Immunol. 37: 1184-1193.
10. Spörri, R., and C. Reis e Sousa. 2005. Inflammatory mediators are insufficient for full dendritic cell activation and promote expansion of CD4+ T cell populations lacking helper function. Nat. Immunol. 6: 163-170.
11. Joffre, O., M. A. Nolte, R. Spö rri, and C. Reis e Sousa. 2009. Inflammatory signals in dendritic cell activation and the induction of adaptive immunity. Immunol. Rev. 227: 234-247.
12. Vega-Ramos, J., and J. A. Villadangos. 2013. Consequences of direct and indirect activation of dendritic cells on antigen presentation: functional implications and clinical considerations. Mol. Immunol. 55: 175-178.
13. Hemmi, H., O. Takeuchi, T. Kawai, T. Kaisho, S. Sato, H. Sanjo, M. Matsumoto, K. Hoshino, H. Wagner, K. Takeda, and S. Akira. 2000. A Toll-like receptor recognizes bacterial DNA. Nature 408: 740-745.
14. Otten, L. A., S. Leibundgut-Landmann, J. Huarte, I. C. Kos-Braun, C. Lavanchy, E. Barras, B. Borisch, V. Steimle, H. Acha-Orbea, andW. Reith. 2006. Revisiting the specificity of the MHC class II transactivator CIITA in vivo. Eur. J. Immunol. 36: 1548-1558.
15. Hogquist, K. A., S. C. Jameson, W. R. Heath, J. L. Howard, M. J. Bevan, and F. R. Carbone. 1994. T cell receptor antagonist peptides induce positive selection. Cell 76: 17-27.
16. Barnden, M. J., J. Allison, W. R. Heath, and F. R. Carbone. 1998. Defective TCR expression in transgenic mice constructed using cDNA-based alpha- and betachain genes under the control of heterologous regulatory elements. Immunol. Cell Biol. 76: 34-40.
17. Köntgen, F., G. Süss, C. Stewart, M. Steinmetz, and H. Bluethmann. 1993. Targeted disruption of the MHC class II Aa gene in C57BL/6 mice. Int. Immunol. 5: 957-964.
18. Vremec, D., J. Pooley, H. Hochrein, L. Wu, and K. Shortman. 2000. CD4 and CD8 expression by dendritic cell subtypes in mouse thymus and spleen. J. Immunol. 164: 2978-2986.
19. Naik, S. H., A. I. Proietto, N. S. Wilson, A. Dakic, P. Schnorrer, M. Fuchsberger, M. H. Lahoud, M. O'Keeffe, Q. X. Shao, W. F. Chen, et al. 2005. Cutting edge: generation of splenic CD8+ and CD8- dendritic cell equivalents in Fms-like tyrosine kinase 3 ligand bone marrow cultures. J. Immunol. 174: 6592-6597.
20. Wilson, N. S., D. El-Sukkari, and J. A. Villadangos. 2004. Dendritic cells constitutively present self antigens in their immature state in vivo and regulate antigen presentation by controlling the rates of MHC class II synthesis and endocytosis. Blood 103: 2187-2195.
21. Villadangos, J. A., R. J. Riese, C. Peters, H. A. Chapman, and H. L. Ploegh. 1997. Degradation of mouse invariant chain: roles of cathepsins S and D and the influence of major histocompatibility complex polymorphism. J. Exp. Med. 186: 549-560.
22. Zhan, Y., Y. Xu, S. Seah, J. L. Brady, E. M. Carrington, C. Cheers, B. A. Croker, L. Wu, J. A. Villadangos, and A. M. Lew. 2010. Resident and monocyte-derived dendritic cells become dominant IL-12 producers under different conditions and signaling pathways. J. Immunol. 185: 2125-2133.
23. Wilson, N. S., D. El-Sukkari, G. T. Belz, C. M. Smith, R. J. Steptoe, W. R. Heath, K. Shortman, and J. A. Villadangos. 2003. Most lymphoid organ dendritic cell types are phenotypically and functionally immature. Blood 102: 2187-2194.
24. Pooley, J. L., W. R. Heath, and K. Shortman. 2001. Cutting edge: intravenous soluble antigen is presented to CD4 T cells by CD8- dendritic cells, but crosspresented to CD8 T cells by CD8+ dendritic cells. J. Immunol. 166: 5327-5330.
25. Dudziak, D., A. O. Kamphorst, G. F. Heidkamp, V. R. Buchholz, C. Trumpfheller, S. Yamazaki, C. Cheong, K. Liu, H.-W. Lee, C. G. Park, et al. 2007. Differential antigen processing by dendritic cell subsets in vivo. Science 315: 107-111.
26. Vremec, D., M. O'Keeffe, A. Wilson, I. Ferrero, U. Koch, F. Radtke, B. Scott, P. Hertzog, J. Villadangos, and K. Shortman. 2011. Factors determining the spontaneous activation of splenic dendritic cells in culture. Innate Immun. 17: 338-352.
27. Schnorrer, P., G. M. N. Behrens, N. S. Wilson, J. L. Pooley, C. M. Smith, D. El-Sukkari, G. Davey, F. Kupresanin, M. Li, E. Maraskovsky, et al. 2006. The dominant role of CD8+ dendritic cells in cross-presentation is not dictated by antigen capture. Proc. Natl. Acad. Sci. USA 103: 10729-10734.
28. den Haan, J. M., S. M. Lehar, and M. J. Bevan. 2000. CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo. J. Exp. Med. 192: 1685-1696.
29. Landmann, S., A. Mühlethaler-Mottet, L. Bernasconi, T. Suter, J. M. Waldburger, K. Masternak, J. F. Arrighi, C. Hauser, A. Fontana, and W. Reith. 2001. Maturation of dendritic cells is accompanied by rapid transcriptional silencing of class II transactivator (CIITA) expression. J. Exp. Med. 194: 379-391.
30. Dadaglio, G., C. A. Nelson, M. B. Deck, S. J. Petzold, and E. R. Unanue. 1997. Characterization and quantitation of peptide-MHC complexes produced from hen egg lysozyme using a monoclonal antibody. Immunity 6: 727-738.
31. ten Broeke, T., G. van Niel, M. H. M. Wauben, R. Wubbolts, and W. Stoorvogel. 2011. Endosomally stored MHC class II does not contribute to antigen presentation by dendritic cells at inflammatory conditions. Traffic 12: 1025-1036.
32. Young, L. J., N. S. Wilson, P. Schnorrer, A. Proietto, T. ten Broeke, Y. Matsuki, A. M. Mount, G. T. Belz, M. O'Keeffe, M. Ohmura-Hoshino, et al. 2008. Differential MHC class II synthesis and ubiquitination confers distinct antigenpresenting properties on conventional and plasmacytoid dendritic cells. Nat. Immunol. 9: 1244-1252.
33. De Gassart, A., V. Camosseto, J. Thibodeau, M. Ceppi, N. Catalan, P. Pierre, and E. Gatti. 2008. MHC class II stabilization at the surface of human dendritic cells is the result of maturation-dependent MARCH I down-regulation. Proc. Natl. Acad. Sci. USA 105: 3491-3496.
34. Simmons, D. P., P. A. Wearsch, D. H. Canaday, H. J. Meyerson, Y. C. Liu, Y. Wang, W. H. Boom, and C. V. Harding. 2012. Type I IFN drives a distinctive dendritic cell maturation phenotype that allows continued class II MHC synthesis and antigen processing. J. Immunol. 188: 3116-3126.
35. Lutz, M. B. 2012. Therapeutic potential of semi-mature dendritic cells for tolerance induction. Front. Immunol. 3: 123.
36. Drutman, S. B., and E. S. Trombetta. 2010. Dendritic cells continue to capture and present antigens after maturation in vivo. J. Immunol. 185: 2140-2146.
37. Segura, E., and J. A. Villadangos. 2009. Antigen presentation by dendritic cells in vivo. Curr. Opin. Immunol. 21: 105-110.